Entos Pharmaceuticals

12/05/2024

Member Spotlight—Entos Pharmaceuticals! Entos Pharmaceuticals is committed to using its Fusogenix™ PLV™ technology to develop cures and improve the lives of patients and their families. Recent advances in the development of high precision genetic therapies have put cures within reach for previously untreatable diseases and conditions. Therapies in development have the potential to eradicate genetic diseases, block cancer, and reverse aging.
Learn more: https://bit.ly/3ZlALvK

11/26/2024

Dr. John Lewis is presenting a CRINA Connects seminar on Wednesday, Nov 27, at noon MT - email crina@ualberta for the Zoom link.

On Wednesday, November 27th, join CRINA and Dr. John Lewis for "Development of highly selective genetic medicines as cancer therapeutics." Email [email protected] for the Zoom link.

11/12/2024

The BIOTECanada Fall 2024 edition of Insights magazine via Issuu is now available digitally. Check out Entos Pharmaceuticals' article - pages 80-81 - where CEO John Lewis and CSO Arun Raturi describe our advanced precision medicines delivery platform!

Read Insights Fall 2024 by BIOTECanada on Issuu and browse thousands of other publications on our platform. Start here!

10/24/2024

Oct 23, 2024 - CEO and Professor John Lewis was on Radio Active with Jessica Ng, and Min Dhariwal talking about a big breakthrough in advanced therapeutics coming from the Lewis lab at the University of Alberta, Duncan lab at Dalhousie University, and Entos Pharmaceuticals.
Go to https://www.cbc.ca/listen/live-radio/1-52-radio-active/clip/16103538-researchers-big-breakthrough-genetic-medicine to listen!

A University of Alberta-led team of researchers has made a huge breakthrough in the field of genetic medicine. They’ve developed a new drug delivery system that could have a major impact on how some medical conditions are treated. John Lewis is one of the lead researchers on the project. He's also...

10/23/2024

Global News reporter Sarah Ryan talked with Entos scientist Doug Brown and John Lewis, Bird Dogs Chair in Translational Oncology at the University of Alberta plus CEO of Entos, about a new medical breakthrough designed to optimize the delivery of potential life-saving advanced medicines.
Doug Brown is the first author of an article recently published in the journal Cell that reported the research results.
Go to www.entospharma.com to learn more.

Watch U of A medical breakthrough could one day cure deadly cancers Video Online, on GlobalNews.ca

10/09/2024

We are excited to share an article recently published in Nature Portfolio's Nature Reviews Drug Discovery by Katie Kingwell that highlights our breakthrough Fusogenix PLV delivery technology work for advanced therapeutics!
The original paper was published on Sept 19 in Cell by Cell Press and can also be found at: https://lnkd.in/gz6-ARd5.

A viral–lipid hybrid delivery system for genetic therapies https://lnkd.in/gCYA2YVR

Discover the world’s best science and medicine | Nature.com

09/10/2024

Excited to share the publication of our groundbreaking research in Cell Press, showing the safe and effective delivery of DNA and RNA using our FAST-PLV platform.

Designed to overcome the limitations of current gene delivery technologies, FAST-PLV has the potential to fully realize the promise of genetic medicine. This milestone marks the beginning of a new era in the field and reinforces our commitment to developing safer, more effective, and re-dosable therapies for patients.

The online publication is available to check out below, with the print issue live on September 19.

Current genetic medicines are limited by tolerability, scalability, and immunogenicity issues. Utilizing components from viral and non-viral delivery platforms, we developed a lipid-based delivery vehicle formulated with a chimeric fusion protein that delivers nucleic acid cargo inside cells effecti...

08/21/2024

We are thrilled to share the launch of our newly refreshed Entos Pharmaceuticals website!
Visit www.entospharma.com and check it out! Featuring our innovative Fusogenix PLV delivery technology, pipeline programs, partnerships, Entos culture, and more. 😊

The Fusogenix PLV platform uses our FAST fusion protein technology to enable delivery by direct fusion, allowing us to create genetic medicines that are safe, effective, and redosable.

04/06/2024

Every week, ‘Good News of the Week’ features a curation of positive headlines from San Diego, delivered straight to your inbox. A blend of aggregated stories from San Diego’s most trusted news sources and original EDC-created content, GNOTW provides a comprehensive recap of the region’s best...

02/01/2024

Feb 1: Manufacturing Dive BRIEF published Feb 1, 2024: Entos Pharmaceuticalsopens Carlsbad, California facility.

The Carlsbad facility will produce messenger RNA and plasmid DNA, part of a broader strategy to expand production in both the U.S. and Canada.